Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Adami

Showing results (141-150 of 212) with videos related to

Pageof 22
Sort By:
Journal of Endocrinological Investigation|July 6, 2000
Prevention of early postmenopausal bone loss with cyclical etidronateS Adami, V Bruni, D Bianchini, et al.
The Journal of Clinical Endocrinology and Metabolism|April 13, 1999
Spironolactone, but not flutamide, administration prevents bone loss in hyperandrogenic women treated with gonadotropin-releasing hormone agonistP Moghetti, R Castello, N Zamberlan, et al.
The Quarterly Journal of Medicine|January 1, 1982
Long-term effects of 1,25-dihydroxy vitamin D3 and 24,25-dihydroxy vitamin D3 in renal osteodystrophyN Muirhead, S Adami, L M Sandler, et al.
Clinical Endocrinology|April 1, 1978
Discriminant analysis in the differential diagnosis of hypercalcaemiaV Lo Cascio, P Vallaperta, S Adami, et al.
Calcified Tissue International|May 1, 1982
Suppressive effect of chronic glucocorticoid treatment on circulating calcitonin in manV LoCascio, S Adami, L V Avioli, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|September 6, 2005
Quantitative heel ultrasound in a population-based study in Italy and its relationship with fracture history: the ESOPO studyS Maggi, M Noale, S Giannini, et al.
Bone and Mineral|May 1, 1994
Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget's disease of boneS Adami, N Zamberlan, M Mian, et al.
Bone and Mineral|August 1, 1987
The use of dichloromethylene bisphosphonate and aminobutane bisphosphonate in hypercalcemia of malignancyS Adami, G P Bolzicco, A Rizzo, et al.
Minerva Medica|July 14, 1979
[Incidence of thyroid diseases in primary hyperparathyroidism]G Galvanini, M Ferrari, S Adami, et al.
Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association|January 1, 1980
Comparison of 1,25(OH)2D3 and 24,25(OH)2D3 in the long-term treatment of renal osteodystrophyN Muirhead, G R Catto, N Edward, et al.
Pageof 22

Showing results (141-150 of 212) with videos related to

Sort By:
Pageof 22
Journal of Endocrinological Investigation|July 6, 2000
Prevention of early postmenopausal bone loss with cyclical etidronateS Adami, V Bruni, D Bianchini, et al.
The Journal of Clinical Endocrinology and Metabolism|April 13, 1999
Spironolactone, but not flutamide, administration prevents bone loss in hyperandrogenic women treated with gonadotropin-releasing hormone agonistP Moghetti, R Castello, N Zamberlan, et al.
The Quarterly Journal of Medicine|January 1, 1982
Long-term effects of 1,25-dihydroxy vitamin D3 and 24,25-dihydroxy vitamin D3 in renal osteodystrophyN Muirhead, S Adami, L M Sandler, et al.
Clinical Endocrinology|April 1, 1978
Discriminant analysis in the differential diagnosis of hypercalcaemiaV Lo Cascio, P Vallaperta, S Adami, et al.
Calcified Tissue International|May 1, 1982
Suppressive effect of chronic glucocorticoid treatment on circulating calcitonin in manV LoCascio, S Adami, L V Avioli, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|September 6, 2005
Quantitative heel ultrasound in a population-based study in Italy and its relationship with fracture history: the ESOPO studyS Maggi, M Noale, S Giannini, et al.
Bone and Mineral|May 1, 1994
Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget's disease of boneS Adami, N Zamberlan, M Mian, et al.
Bone and Mineral|August 1, 1987
The use of dichloromethylene bisphosphonate and aminobutane bisphosphonate in hypercalcemia of malignancyS Adami, G P Bolzicco, A Rizzo, et al.
Minerva Medica|July 14, 1979
[Incidence of thyroid diseases in primary hyperparathyroidism]G Galvanini, M Ferrari, S Adami, et al.
Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association|January 1, 1980
Comparison of 1,25(OH)2D3 and 24,25(OH)2D3 in the long-term treatment of renal osteodystrophyN Muirhead, G R Catto, N Edward, et al.
Pageof 22